The companys entry into obesity combines this antibody expertise with GLP-1 biology, however, its focus is testing whether muscle-preserving antibodies, including trevogrumab, a myostatin inhibitor, can be combined with semaglutide to address the lean-mass loss associated with GLP-1 monotherapy
Williams recommends a conversation between an eye doctor, primary care doctor, and, if pertinent, a neurologist or other subspecialist, to decide how to proceed with the medication
Key moves include: Geographic expansion : Lilly has out-licensed tirzepatide to partners in Asia (e.g., in China and India) to accelerate uptake outside the U.S./EU
How it works: As you eat, metabolic processes are triggered in your body